List of SBIR/STTR awards granted to Aqualung Therapeutics
Aqualung TherapeuticsA STTR Phase I contract was awarded to Aqualung Therapeutics in August, 2019 for $225,000.0 USD from the U.S. Department of Health & Human Services and National Institutes of Health.
A STTR Phase I contract was awarded to Aqualung Therapeutics in June, 2020 for $300,001.0 USD from the U.S. Department of Health & Human Services and National Institutes of Health.
A STTR Phase II contract was awarded to Aqualung Therapeutics in June, 2021 for $1,000,000.0 USD from the U.S. Department of Health & Human Services and National Institutes of Health.
A STTR Phase I contract was awarded to Aqualung Therapeutics in September, 2022 for $259,613.0 USD from the U.S. Department of Health & Human Services and National Institutes of Health.
A STTR Phase I contract was awarded to Aqualung Therapeutics in September, 2022 for $269,233.0 USD from the U.S. Department of Health & Human Services and National Institutes of Health.
A STTR Phase I contract was awarded to Aqualung Therapeutics in September, 2020 for $265,096.0 USD from the U.S. Department of Health & Human Services and National Institutes of Health.
A STTR Phase II contract was awarded to Aqualung Therapeutics in May, 2020 for $750,000.0 USD from the U.S. Department of Health & Human Services and National Institutes of Health.
A STTR Phase I contract was awarded to Aqualung Therapeutics in September, 2022 for $259,613.0 USD from the U.S. Department of Health & Human Services and National Institutes of Health.
A STTR Phase I contract was awarded to Aqualung Therapeutics in June, 2019 for $225,000.0 USD from the U.S. Department of Health & Human Services and National Institutes of Health.
A STTR Phase I contract was awarded to Aqualung Therapeutics for $631,234.0 USD from the U.S. Department of Health & Human Services.
